RGNX — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

14.69

Margin Of Safety %

Put/Call OI Ratio

0.41

EPS Next Q Diff

0.75

EPS Last/This Y

0.97

EPS This/Next Y

0.25

Price

10.73

Target Price

26.5

Analyst Recom

1.5

Performance Q

Upside

-1,337.4%

Beta

0.96

Ticker: RGNX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-14	RGNX	12.29	0.21	0.10	13545
2026-07-15	RGNX	12.28	0.21	0.63	13664
2026-07-16	RGNX	11.2	0.21	0.22	13695
2026-07-17	RGNX	9.88	0.21	0.98	13732
2026-07-20	RGNX	10.31	0.61	0.01	5499
2026-07-21	RGNX	10.33	0.51	1.15	6253
2026-07-22	RGNX	10.2	0.54	0.44	6661
2026-07-23	RGNX	10.24	0.54	0.29	6725
2026-07-24	RGNX	9.73	0.54	0.75	6730
2026-07-27	RGNX	9.69	0.58	1.11	6892
2026-07-28	RGNX	9.59	0.58	1.26	6927
2026-07-29	RGNX	9.61	0.58	4.33	6911
2026-07-30	RGNX	10.12	0.58	0.00	6916
2026-07-31	RGNX	9.68	0.43	0.18	8461
2026-08-03	RGNX	9.96	0.43	0.25	8574
2026-08-04	RGNX	10.3	0.43	0.00	8582
2026-08-05	RGNX	10.49	0.43	0.14	8490
2026-08-06	RGNX	11.27	0.43	0.06	8524
2026-08-07	RGNX	10.71	0.41	1.43	8799
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-14	RGNX	12.31	108.7	-	-2.82
2026-07-15	RGNX	12.28	108.7	-	-2.82
2026-07-16	RGNX	11.20	108.7	-	-2.82
2026-07-17	RGNX	9.86	108.7	-	-2.82
2026-07-20	RGNX	10.31	108.7	-	-2.82
2026-07-21	RGNX	10.33	108.7	-	-2.82
2026-07-22	RGNX	10.20	108.7	-	-2.82
2026-07-23	RGNX	10.23	108.7	-	-2.82
2026-07-24	RGNX	9.73	92.2	-	-2.79
2026-07-27	RGNX	9.69	92.2	-	-2.79
2026-07-28	RGNX	9.59	92.2	-	-2.79
2026-07-29	RGNX	9.60	92.2	-	-2.79
2026-07-30	RGNX	10.10	92.2	-	-2.79
2026-07-31	RGNX	9.69	92.2	-	-2.79
2026-08-03	RGNX	9.97	92.2	-	-2.79
2026-08-04	RGNX	9.97	92.2	-	-2.79
2026-08-05	RGNX	10.48	92.2	-	-2.79
2026-08-06	RGNX	11.27	92.2	-	-2.79
2026-08-07	RGNX	10.73	92.2	-	-2.79
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-14	RGNX	-1.49	-1.14	22.51
2026-07-15	RGNX	-1.49	-1.14	22.51
2026-07-16	RGNX	-1.49	-1.14	22.51
2026-07-17	RGNX	-1.49	-1.14	22.51
2026-07-20	RGNX	-1.49	-1.91	22.51
2026-07-21	RGNX	-1.49	-1.91	22.51
2026-07-22	RGNX	-1.49	-1.91	22.51
2026-07-23	RGNX	-1.49	-1.91	22.51
2026-07-24	RGNX	-1.49	-1.91	22.51
2026-07-27	RGNX	-1.18	-1.60	0
2026-07-28	RGNX	-1.18	-1.60	15.55
2026-07-29	RGNX	-1.18	-1.60	14.69
2026-07-30	RGNX	-1.18	-1.60	14.69
2026-07-31	RGNX	-1.18	-1.60	14.69
2026-08-03	RGNX	-1.18	-1.77	14.69
2026-08-04	RGNX	-1.18	-1.77	14.69
2026-08-06	RGNX	-1.18	-1.77	14.69
2026-08-07	RGNX	-1.18	-1.77	14.69
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

-1.72

Avg. EPS Est. Current Quarter

-0.11

Avg. EPS Est. Next Quarter

-0.97

Insider Transactions

-1.18

Institutional Transactions

-1.77

Beta

0.96

Average Sales Estimate Current Quarter

106

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

76.9

Max Drawdown 5-Year %

-88.4

Target Price

26.5

P/E

Forward P/E

PEG

P/S

4.01

P/B

8.09

P/Free Cash Flow

EPS

-3.79

Average EPS Est. Cur. Y

-2.79

EPS Next Y. (Est.)

-2.54

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-112.58

Relative Volume

0.61

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

EPS 1 30Days Diff

0.12

EBIT Estimation

◆ RGNX Healthcare

$10.72

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

9/25

Volume

9/15

Valuation

12/20

TP/AR

2/10

Options

7/10

RSI

51.6

Range 1M

30.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

12/30

Estimates

0/20

Inst/Vol

0/15

Options

4/10

EPS Yr

22.1%

52W%

49.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +147.2% upside

Quality

6/30

Valuation

16/30

Growth

8/25

Stability

4/10

LT Trend

3/5

Upside

+147.2%

Quality

RGNX — P/E HistoricalBiotechnology

REGENXBIO Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 371

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

RGNX

Latest News

—

Caricamento notizie per RGNX…

stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today

news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance

stock history RGNX – REGENXBIO Inc. invest stock market

stock prices RGNX premarket after hours

ticker RGNX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RGNX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y